Das Colitis ulcerosa-assoziierte Kolonkarzinom

Guido Schürmann; Sabine Ochman; Markus F. Neurath

doi:10.1055/s-2000-7211

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2000; 125(36): 1045-1050
DOI: 10.1055/s-2000-7211

Übersichten

Das Colitis ulcerosa-assoziierte Kolonkarzinom

Risikofaktoren, molekulare Pathogenese und ÜberwachungGuido Schürmann¹ , Sabine Ochman¹ , Markus F. Neurath²

¹Klinik und Poliklinik für Allgemeine Chirurgie der Westfälischen Wilhelms-Universität Münster (Direktor: Prof. Dr. Norbert Senninger)
²I. Medizinische Klinik der Gutenberg Universität Mainz (Direktor: Prof. Dr. Peter Galle)

Abstract

Full Text

References

Literatur

1 Andersen S N, Rognum T O, Bakka A, Clausen O P. Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis. Mol Pathol. 1998; 51 327-332
2 Bernstein C N, Shanahan F, Weinstein W M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet. 1994; 343 71-74
3 Biasco G, BranG, Paganelli G M. et al . Colorectal cancer in patients with ulcerative colitis. Cancer. 1995; 75 2045-2049
4 Blackstone M O, Riddell R H, Rogers B HG, Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis. Gastroenterology. 1981; 80 366-374
5 Brentnall T A, Haggitt R C. et al . Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1996; 110 331-338
6 Broome U, Löfberg R, Veress B, Eriksson L S. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995; 22 1404-1408
7 Broström O, Lofberg R. The risk of colorectal cancer in ulcerative colitis. Scand J Gastroenterol. 1983; 85 22
8 Brüwer M, Schmid K W, WinG, Senninger N, Schürmann G. Expression von p53 und Onkogenen beim Colitis-ulcerosa-assoziierten kolorektalen Karzinom. Langenbecks Arch Chir Suppl. 1999; 1 391-395
9 Burmer G C, Rabinovitch P S, Haggitt R C. et al . Neoplastic progression in ulcerative colitis: histology, DNA content and loss of a p53 allele. Gastroenterolgy. 1992; 103 1602-10
10 Butt J H, Konishi F Morson BC Lennard-Jones JE. Macroscopic lesions in dysplasis and carcinoma complicating ulcerative colitis. Dig Dis Sci. 1983; 28 18
11 Cartwright C A, Coad C A, Egbert B M. Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J Clin Invest. 1994; 93 509-515
12 Choi P M, Nugent F W, Schoetz D J, Silverman M L, Haggitt R C. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993; 105 418-424
13 Connell W R, Lennard-Jones J E. et al . Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994; 107 934-944
14 D¿Haens G, Lashner B A, Hanauer S B. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol. 1993; 88 1174-1178
15 Ekbom A, Helmick C, Zack M, Adami H O. Ulcerative colitis and colorectal cancer. N Engl J Med. 1990; 323 1228-1233
16 Engelsgjerd M, Farraye F A, Odze R D. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999; 117 1288-1294
17 Fogt F, Zhuang Z, Poremba C, Dockhorn-Dworniczak B, Vortmeyer A. Comparison of p53 immunoexpression with allelic loss of p53 in ulcerative colitis-associated dysplasia and carcinoma. Oncol Rep. 1998; 5 477-480
18 Fogt F, Vortmeyer A O, Goldman H. et al . Comparison of genetic alterations in colonic adenoma and colitis-associated dysplasia and carcinoma. Hum Pathol. 1998; 29 131-136
19 Gilat T, Fireman Z, Grossman A. et al . Colorectal cancer in patients with ulcerative colitis:a population study in central israel. Gastroenterology. 1988; 94 870-874
20 Greenstein A J, Sachar D B, Smith H. et al . Cancer in universal and left-sided ulcerative colitis. Gastroenterology. 1979; 77 290-294
21 Greenwald B D, Harpaz N. et al . Loss of heterozygosity affecting the p53, Rb and mcc/apc tumor supressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res. 1992; 52 741-745
22 GySN, Prior P, Allan R N. et al . Colorectal cancer in ulcerative colitis. Gut. 1988; 29 206-217
23 Heuschen G, Heuschen U A, Herfarth C h. Primär sklerosierende Cholangitis - Colitis ulcerosa assoziierte Erkrankung mit chirurgischen Konsequenzen. Chirurg. 1998; 69 1028-1035
24 Holzmann K, Klump B. al . Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer. 1998; 76 1-6
25 Jablonska A M, Reznikova L, Peskova M, Chlumska A, Roth J. Risk of development of colorectal carcinoma in patients with ulcerative colitis. Vnitr Lek. 1993; 39 676-681
26 Katzka I, Brody R S, Morris E, Katz S. Assessment of colorectal cancer risk in patients with ulcerative colitis. Experience from a private pratice. Gastroenterology. 1983; 85 22-29
27 Kim H J, Chuang S K. P53 mutation in patients with ulcerative colitis in rectal biopsy. Korean J Intern Med. 1998; 13 110-116
28 Lang G SM, Heinzlmann M, Stratakis D F, Teschauer W, Loeschke K. Detection of Kiras mutations by PCR and differential hybridization and of p53 mutations by SSCP analysis in endoscopically obtained lavage from patients with long-standing ulcerative colitis. Am J Gastroenterol. 1997; 92 2166-2170
29 Lashner B A, Shapiro B D. et al . Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol. 1997; 94 456-462
30 Lashner B A, Silverstein M D, Hanauer S B. Hazard rates for dysplasia and cancer in ulcerative colitis, results from a surveillance program. Dig Dis Sci. 1989; 34 1536-1541
31 Leidenius M H, Farkkila M A. et al . Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scand J Gastroenterol. 1997; 32 706-711
32 Leidenius M, Kellokumpu I. et al . Dysplasia and carcinoma in lonstanding ulcerative colitis. Gut. 1991; 32 1521-1525
33 Lennard-Jones J E, Melville D M, Morson B C, Ritchie J K, Williams C B. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut. 1990; 31 800-806
34 Levin B. Ulcerative colitis and colon cancer: biology and surveillance. J Cell Biochem Suppl. 1992; 16G 47-50
35 Lo S K, Fleming K A, Chapman R W. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative cholitis using an alkaline phospatase technique. Gut. 1992; 33 1370-1375
36 Lofberg R, Broström O, Karlen P, Tribukait B, Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis- a 15 year follow-up study. Gastroenterology. 1990; 99 1021-31
37 Lofberg R. Studies in longstanding ulcerative colitis with special reference to malignant transformation of the colorectal mucosa. Acta Chir Scand Suppl. 1989; 552 1-45
38 Lynch D AF, Lobo A J, Sobala G M, Dixon M F, Axon A TR. Failure of colonoscopic surveillance in ulcerative colitis. Gut. 1993; 34 1075-1080
39 Mandal A, Dasgupta A, Jeffers L. et al . Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology. 1994; 106 185-192
40 Maratka Z, Nedbal J, Kocianova J, Havelka J, Kudrmann J, Hendl J. Incidence of colorectal cancer in proctocolitis. Gut. 1985; 26 43-49
41 Mayer R, Wong W D, Rothenberger D A, Goldber S M, Madoff R D. Colorectal cancer in inflammatory bowel disease. Dis Col Rec. 1999; 42 343-347
42 Porschen R, Strohmeyer G. Dysplasie und Karzinomrisiko bei Colitis ulcerosa. Dtsch Med Wschr. 1991; 116 1682-1688
43 Riddell R H, Goldman H, Ransohoff D F. et al . Dysplasia in inflammatory bowel disease: standardisized classification with provisional clinical application. Hum Pathol. 1983; 14 931-968
44 Rosenstock E, Farmer R, Petras R, Sivak M V, Rankin G B, SulliBH. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology. 1985; 89 1342-1346
45 Rozen P, Baratz M, Fefer F, Gilat T. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology. 1995; 108 1361-1370
46 Rutegard J N, Ahsgren L R, Janunger K G. Ulcerative colitis. Colorectal cancer risk in an unselected population. Ann Surg. 1988; 208 721-724
47 Sugita A, Greenstein A J, Ribeiro M B. et al . Survival with colorectal cancer in ulcerative colitis. Ann Surg. 1993; 218 189-195
48 Suzuki K, Muto T, Shinozaki M, Yokoyama T, MatsuK, Masaki T. Differential diagnosis of dysplasia-associated lesions or mass and coincidental adenoma in ulcerative colitis. Dis Col Rec. 1998; 11 322-327
49 Vogelstein B, Fearon E R, Hamilton S R. Genetic alterations during colorectal tumor development. N Engl J Med. 1988; 319 525-532
50 Willenbucher R F, Aust D E, Chang C G. et al . Genomic instability is an early event during the progression pathway of ulcerative colitis related neoplasia. Am J Pathol. 1999; 154 1825-1830
51 Yin J, Harpaz N, Tong Y. et al . p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology. 1998; 104 1633-1639

Korrespondenz

Priv.-Doz. Dr. G. Schürmann

Klinik und Poliklinik für Allgemeine Chirurgie der

Westfälischen Wilhelms-Universität Münster

Waldeyerstr. 1

48149 Münster

Phone: 0251 8356310

Fax: 0251 8352400

Email: gschurm@uni-muenster.de